Althea’s cGMP expertise will be combined with Protein’eXpert’s drug and vaccine development offerings.

Althea Technologies and Protein’eXpert plan on offering their services under a complementary commercialization partnership. While Althea Technologies provides manufacturing services,  Protein’eXpert is a contract research organization.

Clients will gain access to Protein’eXpert’s protein engineering, process development, and optimization expertise, with the full realm of cGMP manufacturing resources for production and fill/finish services from Phase I to commercial manufacturing provided by Althea.

The firms hope that the combination of these complementary service will allow both companies to reach larger markets, broaden services for new and challenging products, and to better match early- and late-stage client requirements for protein projects.

“The partnership with Althea Technologies is a great opportunity for us,” remarks Tristan Rousselle, Ph.D., CEO of Protein’eXpert. “Their very strong position on the U.S. market and their outstanding production facilities shall perfectly complement our expertise and set of services based on recombinant protein engineering as well as development- and small-scale cGMP production.”

“We are confident,” states Magda Marquet, president and co-CEO of Althea, “that this will strengthen Althea’s presence in Europe and provide Althea clients valuable early-stage process development capabilities.”

Previous articleInvestigators Find that Mice without IL-21 Are Severely Immunocompromised
Next articleFresenius Snags APP Pharmaceuticals for $3.7B Upfront